放血疗法联合银翘散治疗亚急性甲状腺炎疗效观察

Randomized Controlled Clinical Trial of Yinqiao Powder Combined with Bloodletting in Treatment of Subacute Thyroiditis

目的:观察放血疗法联合银翘散治疗亚急性甲状腺炎的临床疗效。方法:应用随机数字表法将63例符合研究标准的亚急性甲状腺炎患者随机分为2组,观察组32例采用放血疗法联合银翘散加减治疗,对照组31例采用消炎痛、强的松等治疗,2周为1疗程,治疗1疗程后进行疗效、不良反应评定,随访1年后评定复发率。结果:经过1疗程治疗后,观察组总有效率为90.6%,对照组总有效率为67.7%,2组比较,差异有显著性意义(P<0.05)。观察组仅有3例由于放血治疗而导致局部皮下瘀血,不良反应发生率为9.4%;对照组胃肠道不适8例,1例患者由于使用激素而导致面部痤疮,2例患者由于使用激素而导致失眠,不良反应发生率为35.5%,2组比较,差异有显著性意义(P<0.05)。经过1年随访,观察组有2例患者复发,复发率为8.7%;对照组有8例患者复发,复发率为66.7%,2组比较,差异有显著性意义(P<0.05)。结论:放血疗法联合银翘散治疗亚急性甲状腺炎疗效满意,安全可靠。

Objective： To observe the clinical effect of Yinqiao Powder combined with bloodletting in the treatment of subacute thyroiditis（SAT）. Methods： Sixty-three SAT patients were randomized into two groups by using random number table. Thirty-two cases in the observation group were treated with bloodletting combined with Yinqiao Powder, and the other 31 cases in the control group were given pred- nisone and indomethacin orally. The treatment lasted 2 weeks. The efficacy, adverse reactions and relapse rate were observed after treatment. Results： After a course of treatment, the overall efficacy was 90.6% in the observation group and 67.7% in the control group, and the difference was significant（P〈0.05）. In observation group, subcutaneous stagnated blood occurred in 3 cases, and incidence of adverse reaction was 9.4%. In the control group, gastrointestinal discomfort occurred in 8 cases, hormone-induced facial acne occurred in one case, and insomnia occurred in 2 cases, the incidence of adverse reaction being 35.5%. The differences were significant between the two groups（P〈0.05）. The results of one-year fol- low-up showed that recurrence occurred in 2 cases（8.7%） of the observation group and in 8 cases（66.7%） of the control group, the difference being significant（P〈 0.05）. Conclusion. Yinqiao powder combined with bloodletting is effective and safe for the treatment of SAT.